NCT05742607Phase 2Recruiting

IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)

Study sponsor: Innate Pharma

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-06Estimated
Enrollment · participants70Estimated
Source updated2026-06-17Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Primary completion date changed

Before: Jun 2025. After: Jun 2027.

Check registry source